Synthesis and Biological Evaluation of (1-Aryl-1h-pyrazol-4-yl) (3,4,5-Trimethoxyphenyl)methanone Derivatives As Tubulin Inhibitors.

Min'an Zhai,Long Wang,Shiyuan Liu,Lijing Wang,Peng Yan,Junfang Wang,Jingbo Zhang,Haifei Guo,Qi Guan,Kai Bao,Yingliang Wu,Weige Zhang
DOI: https://doi.org/10.1016/j.ejmech.2018.05.058
IF: 7.088
2018-01-01
European Journal of Medicinal Chemistry
Abstract:A series of (1-aryl-1H-pyrazol-4-y1) (3,4,5-trimethoxyphenyl)methanones (8a-p, 9a-p) and ketoxime (10c) derivatives were designed and synthesized as antitubulin agents. All of the target compounds were evaluated for the in vitro anti-proliferative activities against three tumor cell lines (A549, HT-1080, SGC-7901). The most promising compounds in this class were (1-(p-toly1)-1H-pyrazol-4-y1) (3,4,5-trimethoxyphenyl)methanone (9c) and its ketoxime derivative (10c), which significantly inhibited tumor cells growth with IC50 value of 0.054-0.16 jiM. Meanwhile, compound 9c exhibited effectively inhibitory activity of tubulin polymerization. Consistent with its antitubulin activity, compound 9c could destructively damage microtubule network and arrest SGC-7901 cell cycle at G2/M phase significantly. The structure-activity relationship (SAR) and conformational analysis indicate that methyl group at C4-position of C-ring is critical for the activities and the amino group at the C5-position of B-ring plays a negative role in maintaining bioactivity. Furthermore, a molecular docking study was performed to elucidate its binding mode at the colchicine site in the tubulin heterodimer. (C) 2018 Published by Elsevier Masson SAS.
What problem does this paper attempt to address?